Ivermectin's patent status is complex, with many of the original compound patents having expired. However, new patents can be filed for specific formulations, methods of use, or manufacturing processes [1].
When Does Ivermectin Lose Patent Protection?
The fundamental patents for ivermectin, originally developed by Merck, expired decades ago. This means the compound itself is now in the public domain. However, companies can still obtain patents for novel applications or improvements related to ivermectin [1].
Are There New Patents for Ivermectin?
While the original patents have expired, new patent applications related to ivermectin continue to be filed. These may cover specific drug delivery systems, combinations with other drugs, or new therapeutic uses for the compound. DrugPatentWatch.com tracks these developments in patent filings [1].
Can Generic Ivermectin Be Sold?
Yes, because the original compound patents have expired, generic versions of ivermectin can be manufactured and sold. This has led to the availability of ivermectin at lower costs from various pharmaceutical companies [1].
What About New Uses for Ivermectin?
Research into ivermectin continues, and if novel therapeutic uses are discovered and proven effective, these new applications could be patentable. Such patents would protect the specific new use, not the ivermectin compound itself, allowing generic versions for older, established uses to remain available [1].
Who Manufactures Ivermectin Now?
Numerous pharmaceutical companies globally manufacture generic versions of ivermectin. The original developer, Merck, continues to produce ivermectin under its brand names, such as Stromectol, for approved indications [1].
Why Was Ivermectin Initially Patented?
Ivermectin was initially patented by Merck in the 1970s and 1980s due to its status as a novel chemical entity with significant antiparasitic properties. Patents provide market exclusivity for a period, allowing companies to recoup research and development investments [1].